Annual Accounts Payable
$3.22 M
-$297.00 K-8.44%
December 31, 2023
Summary
- As of February 7, 2025, ABUS annual accounts payable is $3.22 million, with the most recent change of -$297.00 thousand (-8.44%) on December 31, 2023.
- During the last 3 years, ABUS annual accounts payable has risen by +$229.00 thousand (+7.65%).
- ABUS annual accounts payable is now -61.04% below its all-time high of $8.27 million, reached on December 31, 2004.
Performance
ABUS Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.31 M
-$337.00 K-12.71%
September 30, 2024
Summary
- As of February 7, 2025, ABUS quarterly accounts payable is $2.31 million, with the most recent change of -$337.00 thousand (-12.71%) on September 30, 2024.
- Over the past year, ABUS quarterly accounts payable has dropped by -$1.43 million (-38.15%).
- ABUS quarterly accounts payable is now -68.03% below its all-time high of $7.24 million, reached on March 31, 2015.
Performance
ABUS Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ABUS Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.4% | -38.1% |
| 3 y3 years | +7.7% | -34.2% |
| 5 y5 years | +1.0% | -34.2% |
ABUS Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.4% | +1.5% | -38.1% | -100.0% |
| 5 y | 5-year | -8.4% | +34.4% | -38.1% | -100.0% |
| alltime | all time | -61.0% | +927.7% | -68.0% | -100.0% |
Arbutus Biopharma Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.31 M(-12.7%) |
| Jun 2024 | - | $2.65 M(-29.1%) |
| Mar 2024 | - | $3.74 M(+16.1%) |
| Dec 2023 | $3.22 M(-8.4%) | $3.22 M(+42.6%) |
| Sep 2023 | - | $2.26 M(+116.5%) |
| Jun 2023 | - | $1.04 M(-57.5%) |
| Mar 2023 | - | $2.46 M(-30.3%) |
| Dec 2022 | $3.52 M(+10.9%) | $3.52 M(+303.7%) |
| Sep 2022 | - | $872.00 K(>+9900.0%) |
| Jun 2022 | - | $0.00(-100.0%) |
| Mar 2022 | - | $1.19 M(-62.4%) |
| Dec 2021 | $3.17 M(+6.0%) | $3.17 M(+204.6%) |
| Sep 2021 | - | $1.04 M(-49.5%) |
| Jun 2021 | - | $2.06 M(+481.1%) |
| Mar 2021 | - | $355.00 K(-88.1%) |
| Dec 2020 | $2.99 M(+24.9%) | $2.99 M(+251.4%) |
| Sep 2020 | - | $852.00 K(-27.9%) |
| Jun 2020 | - | $1.18 M(+127.7%) |
| Mar 2020 | - | $519.00 K(-78.4%) |
| Dec 2019 | $2.40 M(-24.9%) | $2.40 M(+71.3%) |
| Sep 2019 | - | $1.40 M(+104.4%) |
| Jun 2019 | - | $685.00 K(-70.8%) |
| Mar 2019 | - | $2.34 M(-26.6%) |
| Dec 2018 | $3.19 M(+60.6%) | $3.19 M(+3.8%) |
| Sep 2018 | - | $3.08 M(-4.1%) |
| Jun 2018 | - | $3.21 M(+240.2%) |
| Mar 2018 | - | $943.00 K(-52.5%) |
| Dec 2017 | $1.99 M(-38.2%) | $1.99 M(-13.3%) |
| Sep 2017 | - | $2.29 M(-32.0%) |
| Jun 2017 | - | $3.37 M(+108.7%) |
| Mar 2017 | - | $1.61 M(-49.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $3.21 M(+23.2%) | $3.21 M(+55.2%) |
| Sep 2016 | - | $2.07 M(+18.8%) |
| Jun 2016 | - | $1.74 M(-56.3%) |
| Mar 2016 | - | $3.99 M(+53.0%) |
| Dec 2015 | $2.61 M(+27.7%) | $2.61 M(-9.9%) |
| Sep 2015 | - | $2.90 M(+3.4%) |
| Jun 2015 | - | $2.80 M(-61.3%) |
| Mar 2015 | - | $7.24 M(+254.3%) |
| Dec 2014 | $2.04 M(+68.0%) | $2.04 M(-39.7%) |
| Sep 2014 | - | $3.39 M(+90.6%) |
| Jun 2014 | - | $1.78 M(-17.0%) |
| Mar 2014 | - | $2.14 M(+75.9%) |
| Dec 2013 | $1.22 M(+51.0%) | $1.22 M(+56.7%) |
| Sep 2013 | - | $776.80 K(-47.3%) |
| Jun 2013 | - | $1.47 M(+16.4%) |
| Mar 2013 | - | $1.27 M(+57.2%) |
| Dec 2012 | $805.80 K(-36.0%) | $805.80 K(-36.5%) |
| Sep 2012 | - | $1.27 M(+7.8%) |
| Jun 2012 | - | $1.18 M(-8.5%) |
| Mar 2012 | - | $1.29 M(+2.3%) |
| Dec 2011 | $1.26 M(+301.2%) | $1.26 M(+59.5%) |
| Sep 2011 | - | $789.00 K(-58.0%) |
| Jun 2011 | - | $1.88 M(-53.9%) |
| Sep 2008 | - | $4.07 M(-21.6%) |
| Jun 2008 | - | $5.20 M(+3300.9%) |
| Mar 2008 | - | $152.80 K(-51.3%) |
| Dec 2007 | $313.60 K(-75.7%) | $313.60 K(+131.4%) |
| Sep 2007 | - | $135.50 K(-88.3%) |
| Jun 2007 | - | $1.16 M |
| Dec 2005 | $1.29 M(-84.4%) | - |
| Dec 2004 | $8.27 M | - |
FAQ
- What is Arbutus Biopharma annual accounts payable?
- What is the all time high annual accounts payable for Arbutus Biopharma?
- What is Arbutus Biopharma annual accounts payable year-on-year change?
- What is Arbutus Biopharma quarterly accounts payable?
- What is the all time high quarterly accounts payable for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly accounts payable year-on-year change?
What is Arbutus Biopharma annual accounts payable?
The current annual accounts payable of ABUS is $3.22 M
What is the all time high annual accounts payable for Arbutus Biopharma?
Arbutus Biopharma all-time high annual accounts payable is $8.27 M
What is Arbutus Biopharma annual accounts payable year-on-year change?
Over the past year, ABUS annual accounts payable has changed by -$297.00 K (-8.44%)
What is Arbutus Biopharma quarterly accounts payable?
The current quarterly accounts payable of ABUS is $2.31 M
What is the all time high quarterly accounts payable for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly accounts payable is $7.24 M
What is Arbutus Biopharma quarterly accounts payable year-on-year change?
Over the past year, ABUS quarterly accounts payable has changed by -$1.43 M (-38.15%)